Insulin pump therapy is increasing in T2D but real-world use has not been well studied. This report describes insulin delivery and glucose data from adults with T2D using a tubeless insulin pump (Omnipod® Insulin Management System, Acton, MA) with an integrated blood glucose (BG) meter (Abbott Diabetes Care Inc., Alameda, CA) and data management system (DMS; Glooko, Mountain View, CA). Pump system usage data uploaded to the DMS from Feb.-Aug. 2019 were linked to a database of self-reported demographic data and de-identified. Insulin and BG data from ≥3 mo of system use per user were analyzed.

Adults (n=1,202) were aged (mean±SD) 58±11 yr: 47% female, 28% aged ≥65 yr. Total daily insulin was 61±29 units/d delivered as 60±16% basal. Percentage of total daily insulin from basal delivery was ≥50% for 73% of users, and ≥70% for 26%. Only 4.5% and 0.6% of users received ≥90% or <20% of daily insulin from basal delivery, respectively. Users bolused 3.5±1.9 x/d, with 7.8±4.5 units/bolus. Average bolus frequency was ≥1x/d for 95% of users, ≥2x/d for 81%, ≥3x/d for 55%, ≥4x/d for 29%, and ≥5x/d for 16%. About 1 in 5 regularly used the extended bolus or temporary basal rate features (EB/TBR, ≥3.33% of days with gaps <60 days, ≥3mo of use). BG test frequency was 2.1±1.5 x/d for those who used the integrated BG meter (n=853). Among these users, those who bolused <3 x/d (n=387) had a mean BG of 180±52 mg/dL, while those who bolused ≥3 x/d (n=466) had a mean BG of 167±36 mg/dL (p<0.001). Regular EB/TBR users (n=189) had a mean BG of 162±36 vs. 176±46 mg/dL for infrequent users (<3.33% of days, n=619, p<0.001).

These real-world data demonstrate positive self-management behaviors among a large cohort of adults with T2D using a tubeless insulin pump. Both basal and bolus insulin delivery were used by ≥95%, with 81% bolusing at least twice per day, and 22% using EB/TBR features. These results support the tubeless pump as a practicable option for those with T2D requiring insulin therapy.


I.B. Hirsch: Consultant; Self; Abbott, Bigfoot Biomedical, Roche Diabetes Care. Research Support; Self; Medtronic, Omnipod. R.S. Weinstock: Board Member; Self; JDRF. Consultant; Self; Insulogic LLC. Research Support; Self; Boehringer Ingelheim International GmbH, Diasome Pharmaceuticals, Inc., Eli Lilly and Company, Insulet Corporation, Jaeb Center for Health Research, Kowa Research Institute, Inc., Medtronic, Tolerion, Inc. L.M. Huyett: Employee; Self; Insulet Corporation. J. Jantz: Employee; Self; Insulet Corporation. A. Chang: Employee; Self; Insulet Corporation. Stock/Shareholder; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation. Stock/Shareholder; Self; Insulet Corporation. T.T. Ly: Employee; Self; Insulet Corporation.


Insulet Corporation

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at